How to buy Exicure stock

Exicure is a biotechnology business based in the US. Exicure shares (XCUR) are listed on the NASDAQ and all prices are listed in US Dollars. Exicure employs 7 staff and has a trailing 12-month revenue of around $23.8 million.

Exicure stock price (NASDAQ: XCUR)

Use our graph to track the performance of XCUR stocks over time.

Exicure shares at a glance

• Key figures

Information last updated 2023-09-17.

Latest market close	$0.74
52-week range	$0.63 - $1.96
50-day moving average more info button	$1.02
200-day moving average more info button	$1.08
Wall St. target price	$2.00
PE ratio more info button	0.526
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$1.73

Buy Exicure stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Is it a good time to buy Exicure stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exicure price performance over time

Historical closes compared with the close of $0.74 from 2023-09-20

1 week (2023-09-15)	-20.43%
1 month (2023-08-22)	-9.42%
3 months (2023-06-22)	-39.34%
6 months (2023-03-22)	-24.87%

1 year (2022-09-22)	-52.56%
2 years (2021-09-22)	-42.19%
3 years (2020-09-22)	1.92
5 years (2018-09-21)	4.93

Is Exicure stock undervalued or overvalued?

Valuing Exicure stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Exicure's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Exicure financials

Revenue TTM	$23.8 million
Operating margin TTM	13.49%
Gross profit TTM	$9.1 million
Return on assets TTM	7.36%
Return on equity TTM	56.4%
Profit margin	12.88%
Book value	$1.12
Market Capitalization more info button	$7.9 million

TTM: trailing 12 months

Exicure share dividends

We're not expecting Exicure to pay a dividend over the next 12 months.

Have Exicure's shares ever split?

Exicure's shares were split on a 1:30 basis on 29 June 2022. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Exicure shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Exicure shares which in turn could have impacted Exicure's share price.

Exicure share price volatility

Over the last 12 months, Exicure's shares have ranged in value from as little as $0.63 up to $1.96. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exicure's is 1.1309. This would suggest that Exicure's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Exicure overview

Exicure, Inc. , an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. .

Frequently asked questions

What percentage of Exicure is owned by insiders or institutions?
Currently 90.237% of Exicure shares are held by insiders and 10.935% by institutions. How many people work for Exicure?
Latest data suggests 7 work at Exicure. When does the fiscal year end for Exicure?
Exicure's fiscal year ends in December. Where is Exicure based?
Exicure's address is: 2430 North Halsted Street, Chicago, IL, United States, 60614 What is Exicure's ISIN number?
Exicure's international securities identification number is: US30205M1018 What is Exicure's CUSIP number?
Exicure's Committee on Uniform Securities Identification Procedures number is: 30205M101